RU2008151693A - METHOD FOR PREVENTION AND / OR TREATMENT OF DEPENDENCE ON PSYCHOACTIVE SUBSTANCES - Google Patents
METHOD FOR PREVENTION AND / OR TREATMENT OF DEPENDENCE ON PSYCHOACTIVE SUBSTANCES Download PDFInfo
- Publication number
- RU2008151693A RU2008151693A RU2008151693/14A RU2008151693A RU2008151693A RU 2008151693 A RU2008151693 A RU 2008151693A RU 2008151693/14 A RU2008151693/14 A RU 2008151693/14A RU 2008151693 A RU2008151693 A RU 2008151693A RU 2008151693 A RU2008151693 A RU 2008151693A
- Authority
- RU
- Russia
- Prior art keywords
- gene
- dopamine
- receptor
- genetic
- violation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 16
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 239000000126 substance Substances 0.000 title claims abstract 3
- 230000002068 genetic effect Effects 0.000 claims abstract 14
- 230000004060 metabolic process Effects 0.000 claims abstract 14
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract 8
- 108700028369 Alleles Proteins 0.000 claims abstract 6
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims abstract 6
- 108090000357 Dopamine D4 receptors Proteins 0.000 claims abstract 6
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims abstract 6
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims abstract 6
- 108010062431 Monoamine oxidase Proteins 0.000 claims abstract 6
- 102000010909 Monoamine Oxidase Human genes 0.000 claims abstract 5
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 claims abstract 4
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 claims abstract 4
- 229960003638 dopamine Drugs 0.000 claims abstract 4
- 229940076279 serotonin Drugs 0.000 claims abstract 4
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract 2
- 101150050480 SS gene Proteins 0.000 claims abstract 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims abstract 2
- 239000000654 additive Substances 0.000 claims abstract 2
- 238000003748 differential diagnosis Methods 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 238000012544 monitoring process Methods 0.000 claims abstract 2
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 101150012893 dat gene Proteins 0.000 claims 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
1. Способ профилактики и/или лечения зависимости от психоактивных веществ, характеризующийся тем, что включает дифференциальную диагностику причин нарушения по генетическому нейромедиаторному обмену, психологическое тестирование и назначение биологически активных добавок и/или лекарственных препаратов с последующим контролем психологического состояния путем психологического тестирования. ! 2. Способ по п.2, характеризующийся тем, что нарушение по генетическому нейромедиаторному обмену определяют по 1/1 гену рецептора дофамина D2, 7 аллеля гену рецептора дофамина D4, 9/10 гену переносчика дофамина, 1/1 гену бетагидроксилазы дофамина. ! 3. Способ по п.2, характеризующийся тем, что нарушение по генетическому нейромедиаторному обмену определяют по SS гену переносчика серотонина, SL гену переносчика серотонина, с/с гену ресептора серотонина 2С, c/g гену ресептора серотонина 2С, 9/10 ген переносчик дофамина. ! 4. Способ по п.2, характеризующийся тем, что нарушение по генетическому нейромедиаторному обмену определяют по «3-repeat» гену моноаминооксидазы МАО-А, а/а гену моноаминооксидазы МАО-В. ! 5. Способ по п.2, характеризующийся тем, что нарушение по генетическому нейромедиаторному обмену определяют по 9/10 гену переносчика дофамина, 2/2 гену бетагидроксилазы дофамина. ! 6. Способ по п.2, характеризующийся тем, что нарушение по генетическому нейромедиаторному обмену определяют по 1/1 гену рецептора дофамина D2, 7 аллеля гену рецептора дофамина D4, 9/10 гену переносчика дофамина DAT, 1/1 гену бетагидроксилазы дофамина, g/g гену рецептора серотонина 2С, LL гену переносчика серотонина. ! 7. Способ по п.2, характеризующийся тем, что нарушение по генети� 1. A method for the prevention and / or treatment of dependence on psychoactive substances, characterized in that it includes differential diagnosis of the causes of disorders by genetic neurotransmitter metabolism, psychological testing and the appointment of biologically active additives and / or drugs with subsequent monitoring of the psychological state through psychological testing. ! 2. The method according to claim 2, characterized in that the violation of the genetic neurotransmitter metabolism is determined by 1/1 of the dopamine D2 receptor gene, 7 alleles to the dopamine D4 receptor gene, 9/10 dopamine transporter gene, 1/1 dopamine beta-hydroxylase gene. ! 3. The method according to claim 2, characterized in that the violation of the genetic neurotransmitter metabolism is determined by the SS gene of the serotonin carrier, SL gene of the serotonin carrier, s / s gene of the serotonin receptor 2C, c / g gene of the serotonin receptor 2C, 9/10 carrier gene dopamine. ! 4. The method according to claim 2, characterized in that the violation of the genetic neurotransmitter metabolism is determined by the "3-repeat" gene of the monoamine oxidase MAO-A, and / a gene of the monoamine oxidase MAO-B. ! 5. The method according to claim 2, characterized in that the violation of the genetic neurotransmitter metabolism is determined by 9/10 dopamine transporter gene, 2/2 dopamine betahydroxylase gene. ! 6. The method according to claim 2, characterized in that the violation of the genetic neurotransmitter metabolism is determined by 1/1 of the dopamine D2 receptor gene, 7 alleles of the dopamine D4 receptor gene, 9/10 of the dopamine DAT transporter gene, 1/1 of the dopamine beta-hydroxylase gene, g / g serotonin 2C receptor gene, LL serotonin transporter gene. ! 7. The method according to claim 2, characterized in that the violation of geneti
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008151693/15A RU2402974C2 (en) | 2008-12-26 | 2008-12-26 | Method of prevention and/or treatment of psychoactive substance dependence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008151693/15A RU2402974C2 (en) | 2008-12-26 | 2008-12-26 | Method of prevention and/or treatment of psychoactive substance dependence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008151693A true RU2008151693A (en) | 2010-07-10 |
| RU2402974C2 RU2402974C2 (en) | 2010-11-10 |
Family
ID=42684136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008151693/15A RU2402974C2 (en) | 2008-12-26 | 2008-12-26 | Method of prevention and/or treatment of psychoactive substance dependence |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2402974C2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2505820C1 (en) * | 2012-06-06 | 2014-01-27 | Общество с ограниченной ответственностью "ДИАМЕДИКА" (ООО "ДИАМЕДИКА") | Method for integrated assessment of genetic predisposition to development of psychoactive substance abuse |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2190952C1 (en) * | 2001-07-24 | 2002-10-20 | Закрытое акционерное общество "Биосвязь" | Method for treating opium addiction complicated with neurocirculatory dystonia at acute period in young people |
| RU2243757C2 (en) * | 2001-08-09 | 2005-01-10 | Маршак Яков Иммануэлевич | Method for preventing narcomania and/or alcoholism or treating and/or rehabilitation in narcomania and/or alcoholism-suffering patients |
| RU2252756C1 (en) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Preparation and method for producing the preparation for treating alcoholism and drug addiction |
-
2008
- 2008-12-26 RU RU2008151693/15A patent/RU2402974C2/en active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2402974C2 (en) | 2010-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Connolly et al. | Pharmacological treatment of Parkinson disease: a review | |
| Lindenmayer et al. | A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities | |
| Grimbergen et al. | Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus | |
| Martínez‐Fernández et al. | The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations | |
| Poewe et al. | Pharmacologic treatment of motor symptoms associated with Parkinson disease | |
| Trenkwalder et al. | Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double‐blind, randomized, placebo‐controlled study (RECOVER) | |
| Schwartz et al. | Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial | |
| Ballester et al. | Pharmacological treatments for methamphetamine addiction: current status and future directions | |
| Jaunarajs et al. | Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat | |
| Srinivasan et al. | Melatonin in mood disorders | |
| Gasull-Camós et al. | Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats | |
| Thanvi et al. | Long term motor complications of levodopa: clinical features, mechanisms, and management strategies | |
| Schapira | Present and future drug treatment for Parkinson’s disease | |
| Devos et al. | Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease | |
| Whitfield et al. | Classics in chemical neuroscience: levodopa | |
| Stocchi et al. | Rasagiline for the treatment of Parkinson’s disease: an update | |
| Doyle et al. | Pharmacotherapy to control behavioral symptoms in children with autism | |
| DK1656122T4 (en) | Transdermal drug preparations with combinations of active substances to treat Parkinson's disease | |
| Samanta et al. | Duodenal levodopa infusion for the treatment of Parkinson’s disease | |
| EA200801826A1 (en) | DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICINES CONTAINING INDICATED COMPOUNDS | |
| Larner | Cholinesterase inhibitors: beyond Alzheimer’s disease | |
| Yamamoto et al. | Dopamine agonists in Parkinson’s disease | |
| RU2008151693A (en) | METHOD FOR PREVENTION AND / OR TREATMENT OF DEPENDENCE ON PSYCHOACTIVE SUBSTANCES | |
| Youdim et al. | Monoamine oxidase A and B inhibitors in Parkinson's disease | |
| Gershanik et al. | Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20111128 |
|
| QB4A | Licence on use of patent |
Free format text: LICENCE Effective date: 20120305 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20120810 |
|
| QC41 | Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right |
Free format text: LICENCE FORMERLY AGREED ON 20120305 Effective date: 20120810 |
|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -PC4A- IN JOURNAL: 26-2012 |
|
| QB4A | Licence on use of patent |
Free format text: LICENCE Effective date: 20140224 |
|
| PD4A | Correction of name of patent owner |